A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery

NCT03035864 | Completed Phase 2 Results

• 1 other identifier: NGF0116
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery. The main criteria for evaluation were:

• Change from baseline in SANDE scores for severity and frequency assessed at 8 weeks of treatment (primary efficacy endpoint)
• Changes in Cornea vital staining with fluorescein (National Eye Institute \[NEI\] scales) assessed at 8 weeks of treatment (co-primary efficacy endpoint)
• Changes in conjunctiva vital staining with fluorescein (NEI scales) (secondary efficacy endpoint);
• Changes in Tear Film Break-Up Time (TFBUT)(secondary efficacy endpoint);
• Changes in Cochet-Bonnet corneal aesthesiometry (secondary efficacy endpoint);
• Changes in Nerve count and morphology at scanning laser in vivo corneal confocal microscopy (only patients who had Laser-Assisted In situ Keratomileusis \[LASIK\] surgery) (secondary efficacy endpoint);
• Changes in SANDE scores (face values) for severity and frequency (secondary efficacy endpoint);
• Incidence and frequency of treatment-emergent adverse events (TEAEs), assessed throughout the study (safety endpoint).

Conditions

Ocular Discomfort

Keywords

Ocular discomfort after cataract and refractive surgery; cataract surgery; refractive surgery

Outcome Measures

Primary Outcomes (2)

• Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment.

  The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

  Baseline and Week 8

• Changes in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)

  Corneal Staining was derived as the sum of scores of the five corneal sectors (central, superior, inferior, nasal, and temporal) each of which was scored on a scale of 0-3, with a minimum score of 0 and a maximal score of 15 (sum \> 3 out of 15 is abnormal).

  Baseline and Week 8

Secondary Outcomes (4)

• Changes in Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)

  From baseline to weeks 4, 8 and 12

• Changes in Tear Film Break-Up Time (TFBUT)

  From baseline to weeks 4, 8 and 12

• Changes in Cochet-Bonnet Corneal Aesthesiometry

  From baseline to week 8

• Changes in SANDE Scores (Face Values) for Frequency and Severity

  From baseline to weeks 4, 8 and 12

Study Arms (2)

rhNGF 20 µg/ml

EXPERIMENTAL

Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily

Drug: rhNGF

Vehicle

PLACEBO COMPARATOR

Vehicle eye drops six times daily

Other: Vehicle

Interventions

rhNGF DRUG

Eye Drop 20 μg/mL

Also known as: NGF

rhNGF 20 µg/ml

Vehicle OTHER

Vehicle Eye Drop

Vehicle

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female ≥18 years old
• Patients who are characterized by the following clinical features:
• History of cataract or refractive corneal surgery in the study eye(s) in the previous 6 months;
• Mean Symptom Assessment in Dry Eye (SANDE) score for severity and frequency of at least 30 at baseline
• The same eye (study eye) must fulfill all the above criteria
• Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrolment
• Female patients must have negative pregnancy urine test if at childbirth potential.
• Only patients who satisfy all requirements for informed consent may be included in the study. Written Informed Consent must be obtained before the initiation of any study-specific procedures.
• Patients must have the ability and willingness to comply with study procedures

You may not qualify if:

• Any ocular disease other than Dry Eye requiring treatment with topical medications in either eye at the time of study enrolment.
• Any active ocular infection or active inflammation in either eye unrelated to Dry Eye.
• Presence or history of any systemic or ocular disorder, condition or disease (with particular attention to malignancies and neuro-oncological diseases) that could possibly interfere with the conduct of the required study procedures or the interpretation of the study results.
• Use of therapeutic or Refractive Contact lenses in either eye at the time of study enrolment;
• History of ocular surgery in the study eye(s), excluding corneal refractive or cataract procedures, within 90 days of study enrolment.
• Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
• are currently pregnant or,
• have a positive result at the urine pregnancy test (Baseline/Day 0) or,
• intend to become pregnant during the study treatment period or,
• are breast-feeding or,
• are not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected - and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD (Intrauterine device) - during the entire course of and 30 days after the study treatment periods.
• Participation in another clinical study at the same time as the present and within 30 days of study enrolment;
• History of drug, medication or alcohol abuse or addiction.

Sponsors & Collaborators

• Dompé Farmaceutici S.p.A: lead

Study Sites (1)

Univ. G. D'Annunzio-Clinica Oftalmologica-Chieti

Chieti, Italy

Location

MeSH Terms

Interventions

Nerve Growth Factor

Intervention Hierarchy (Ancestors)

Nerve Growth Factors; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Nerve Tissue Proteins; Biological Factors

Limitations and Caveats

LImitations and caveats non specified

Results Point of Contact

• Title: Clinical Development & Operations
• Organization: Dompé farmaceutici s.p.a.

clinical.trials@dompe.com

+39 02 583831

Study Officials

• Leonardo Mastropasqua, MD

  Univ. G. D'Annunzio- Clinica Oftalmologica Chieti

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: For the whole duration of the trial, treatment was unknown to the patient, the Investigator and the site staff.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 23, 2017
• First Posted: January 30, 2017
• Study Start: January 12, 2017
• Primary Completion: September 4, 2017
• Study Completion: September 4, 2017
• Last Updated: April 19, 2024
• Results First Posted: July 22, 2019

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)